JAK1 and colitis: For example, JAK1 inhibitor Filgotinib was approved for UC treatment optimized via a combination of virtual kinase selectivity profiling, cytokine suppression in co-cultured T-cell/epithelial systems, and targeted efficacy testing in murine colitis models [197].